Home / News

SASOP Statement on Use of IVI Ketamine and Intranasal Esketamine for TRD

Despite the proven efficacy of monoamine-based antidepressants, many treated individuals fail to achieve full syndromic and functional recovery, especially with repeated episodes. Ketamine and Esketamine represents novel treatment opportunities in the management of patients with treatment resistant depression (TRD) in Major Depressioni

Read More

Integrating Biological and Psychological explanations of recovery by utilizing both Ketamine and Sandplay Therapies concurrently

Due to the transpersonal nature of the Ketamine experience, a Jungian framework that addresses archetypal concepts particularly centred on the estrangement and reconciliation of the Ego-Self Axis, is a valuable post-infusion Psychotherapeutic mode of healing.

Read More

APA publishes best-practice guidance for ketamine in TRD

Ketamine and esketamine have grown in popularity as agents to manage treatment-resistant depression (TRD). Althoughketamine has several routes of administration, the best record for efficacy against TRD has been recorded with theintravenous (IV) and intranasal routes.

Read More

SASA releases a statement on outpatient ketamine infusions

Ketamine infusions for the management of severe depression have gained popularity in recent years worldwide, with literature suggesting that it is an efficacious, viable and safe treatment modality if provided by experienced practitioners and within appropriate specialist guidelines.

Read More